Literature DB >> 6167794

Anthracycline-associated cardiac and renal damage in rabbits. Evidence for mediation by vasoactive substances.

M R Bristow, W A Minobe, M E Billingham, J B Marmor, G A Johnson, B M Ishimoto, W S Sageman, J R Daniels.   

Abstract

We tested the hypothesis that anthracycline-induced cardiac and renal damage is mediated by vasoactive substances. A 1-minute exposure to 5 micrograms per ml. of doxorubicin (DXR, Adriamycin) produced cardiac histamine release in isolated rabbit hearts. Under conditions in which histamine uptake and metabolism were impaired, the administration of DXR, 2 mg. per kg., over 1 minute was associated with elevations in arterial histamine and catecholamines. The chronic weekly administration of DXR produced severe cardiac and renal damage. The administration of combined histaminic and adrenergic blockade with diphenhydramine, cimetidine, phentolamine, and propranolol (DCPP) pre- and immediately post-DXR resulted in near total protection against DXR-mediated cardiac damage and prevented the majority of the renal lesions. The combined administration of diphenhydramine, cimetidine, phentolamine, and propranolol did not appear to be acting by mechanisms other than blockade of vasoactive amine receptors as cardiac uptake of DXR and the DXR antitumor response were not altered by diphenhydramine, cimetidine, phentolamine, and propranolol. This study demonstrates that anthracycline-associated cardiac and renal toxicity may be mediated by vasoactive substances and that anthracycline cardiomyopathy is potentially preventable.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6167794

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  20 in total

1.  Significance of adaptation mechanisms in adriamycin induced congestive heart failure.

Authors:  P K Singal; N Siveski-Iliskovic; N Kaul; M Sahai
Journal:  Basic Res Cardiol       Date:  1992 Nov-Dec       Impact factor: 17.165

2.  Effects of pirarubicin, an antitumor antibiotic, on the cardiovascular system.

Authors:  S Hirano; N Agata; Y Hara; H Iguchi; M Shirai; H Tone; N Urakawa
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

3.  Cardiotoxic effects of anthracyclines.

Authors:  M R Bristow
Journal:  West J Med       Date:  1983-09

Review 4.  A risk-benefit assessment of anthracycline antibiotics in antineoplastic therapy.

Authors:  R Abraham; R L Basser; M D Green
Journal:  Drug Saf       Date:  1996-12       Impact factor: 5.606

5.  H2 receptor antagonists and right ventricular morphology: the MESA right ventricle study.

Authors:  Peter J Leary; R Graham Barr; David A Bluemke; Michael R Bristow; Richard A Kronmal; Joao A Lima; David D Ralph; Corey E Ventetuolo; Steven M Kawut
Journal:  Ann Am Thorac Soc       Date:  2014-11

6.  Effects of cardiac-restricted overexpression of the A(2A) adenosine receptor on adriamycin-induced cardiotoxicity.

Authors:  Eman A Hamad; Xue Li; Jianliang Song; Xue-Qian Zhang; Valerie Myers; Hajime Funakoshi; Jin Zhang; Jufang Wang; Jifen Li; David Swope; Ashley Madonick; John Farber; Glenn L Radice; Joseph Y Cheung; Tung O Chan; Arthur M Feldman
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-04-02       Impact factor: 4.733

Review 7.  Anaesthesia and allergic drug reactions.

Authors:  G C Moudgil
Journal:  Can Anaesth Soc J       Date:  1986-05

Review 8.  Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy.

Authors:  G L Plosker; D Faulds
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

9.  Cardiovascular autonomic function in anthracycline-treated breast cancer patients.

Authors:  M Viniegra; M Marchetti; M Losso; A Navigante; S Litovska; A Senderowicz; L Borghi; J Lebron; D Pujato; H Marrero
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

10.  Cardiac matrix alterations induced by adriamycin.

Authors:  J B Caulfield; V Bittner
Journal:  Am J Pathol       Date:  1988-11       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.